Accelleron Industries holds the cleaner structural position, with profitability as the main driver and valuation adding further support. Neurocrine Biosciences still has the edge on valuation, which keeps the comparison from looking entirely one-sided. The market setup is currently leaning toward Neurocrine Biosciences, which does not confirm the structural lead. That leaves a split case: the structural lead stays with Accelleron Industries, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (ACLN.SW: STOXX 600, NBIX: Russell 1000).
The clearest separation starts in profitability, with growth adding a second layer of support. Accelleron Industries AG leads by 8 points on the overall comparison score.
These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.
A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.
Most of the shared profile comes through recent revenue growth and capital structure.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Accelleron Industries AG still looks stronger overall, though current pricing looks more supportive for Neurocrine Biosciences, Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where ACLN.SW and NBIX each sit in their own 3.9-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
Capital efficiency adds support, with a 28-point ROIC advantage.
Absolute pricing still looks more supportive for Neurocrine Biosciences, with a forward P/E that is 15.3 turns lower there.
The profitability lead is clear, but pricing and valuation still pull in the other direction — the result holds, but not without friction.
Break down the ACLN.SW vs NBIX comparison across all dimensions with the full interactive tool.
Explore how ACLN.SW and NBIX each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.